Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Nucleic Acid Based Gene Therapy Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The nucleic acid based gene therapy market has demonstrated significant growth in recent years. This market is projected to expand from $0.88 billion in 2025 to $0.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. Historically, this expansion has been driven by several factors, including advancements in molecular biology research, a deeper understanding of genetic disease mechanisms, the expansion of clinical trials for gene therapies, rising investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.
The nucleic acid based gene therapy market is anticipated to undergo substantial expansion in the forthcoming years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. This growth over the projected period can be attributed to several factors, including the increasing integration of CRISPR-based treatments, a growing demand for therapies addressing rare diseases, the expansion of facilities for gene therapy manufacturing, an intensifying focus on personalized oncology treatments, and an uptick in public and private funding directed towards genetic medicine. Noteworthy trends for the forecast period encompass a rising adoption of RNA-based therapeutics, increased utilization of both viral and non-viral gene delivery systems, a stronger emphasis on targeted gene editing technologies, the broadening availability of personalized genetic therapies, and an enhanced focus on precision medicine applications.
Get A Free Sample Report With In-Depth Market Insights:
Nucleic Acid Based Gene Therapy Market Demand Drivers: What’s Powering Industry Growth?
The future expansion of the nucleic acid based gene therapy market is anticipated to be driven by increasing financial backing from governments and private enterprises. This financial backing encompasses monetary investments, grants, or subsidies originating from public or private entities, aimed at advancing the research, development, and market availability of these treatments. The surge in financial aid stems from a heightened global focus on finding remedies for rare and genetic ailments that currently have no effective cures. Government funding specifically accelerates advancements in nucleic-acid–based gene therapy by providing critical resources for research, clinical trials, and infrastructure, which directly fosters innovation and the development of practical treatments. For example, in July 2023, the U.S. National Institutes of Health, a U.S.-based federal health research agency, allocated over $140 million to expedite genome editing methods, including CRISPR and other nucleic acid technologies, for rare neurological and blood disorders. This represents a substantial rise from the $92 million in annual funding provided in 2022. Consequently, the growing financial support from governments and companies is propelling the growth of the nucleic acid based gene therapy market.
Nucleic Acid Based Gene Therapy Market Segment Breakdown: Which Categories Lead On Revenue?
The nucleic acid based gene therapy market covered in this report is segmented –
1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes
Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)
Nucleic Acid Based Gene Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies operating in the nucleic acid-based gene therapy market are focusing on personalized, autologous stem-cell therapies, such as genetically modified hematopoietic stem-cell infusions, to treat rare inherited diseases. Autologous therapies refer to treatments in which a patient’s own stem cells are removed, genetically corrected and re-infused to restore the missing biochemical function. For instance, in March 2024, Orchard Therapeutics, a US-based company that offers pharmaceuticals announced Lenmeldy (atidarsagene autotemcel) approved by the U.S. Food and Drug Administration for children with metachromatic leukodystrophy (MLD). Lenmeldy uses the patient’s own hematopoietic stem cells that have been genetically modified to express a functional ARSA gene, enabling enzyme restoration in the nervous system. This regulatory success underscores how companies can commercialize complex, autologous gene therapies despite high manufacturing costs.
Nucleic Acid Based Gene Therapy Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
View The Full Nucleic Acid Based Gene Therapy Market Report:
Nucleic Acid Based Gene Therapy Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model